iPSC line collection

High–quality iPSC derived lines from patient and control human donors

Commercially available and consented iPSC lines

We have an extensive commercial library iPSCs from a range of patient and healthy donors. The cell lines include those from healthy donors and those with: 

Our axoLinesTM iPSCs are used for axoServicesTM custom lab services, custom differentiated axoCellsTM projects and specific licensing arrangements. 

A  library of high-quality iPSC-derived lines from unaffected and patient donors, the portfolio is strengthened through strategic collaborations including with StrataStem to deliver stratified sporadic Alzheimer’s disease models, the PRISM ALS consortia with LifeArc and ALS TDI to democratise access to diverse, patient-derived ALS models for researchers worldwide and other academic research institutes and patient advocacy groups.

Unaffected donors iPSCs 

Unaffected CFH p.Y402H +/+; ARMS2 p.A69S +/+; HTRA1 rs1120063 +/+ M 30
CFH p. Y402H +/+; ARMS2;  p.A69S +/+; HTRA1 rs11200638 +/+ M 45
CFH p.Y402 +/+ F 84
MERTK +/- p.H721Q F 51
ATN1 CAG 12/13 +/+ F 45

Patient donor iPSCs

Mutation Sex Age
ALS C9orf72 >100 G4C2 +/- F 44
SOD1 p.D109Y +/- F 61
C9orf72 >145 G4C2 +/- F 64
C9orf72 >145 G4C2 +/- M 62
ALS/FTD TARDBP p.A382T +/- F 62
AD APOE E3/E3 F 59
APOE E3/E4 M 60
APOE E3/E4 F 52
APOE E3/E3 M 83
APOE E4/E4 F 69
APOE E3/E3 M 80
APOE E3/E4 M 74
APOE E4/E4 F 76
APOE E3/E4 M 82
APOE E3/E4 F 72
APOE E3/E3 F 79
APOE E3/E3 M 70
APOE E3/E3 M 81
APOE E2/E3 M 73
APOE E3/E4 M 70
APOE E3/E4 M 77
APOE E3/E4 M 72
APOE E2/E3 M 77
APOE E3/E4 F 52
AMD CFH p.Y402H -/-; ARMS2 p.A69S -/-;            C3 p. R102G +/-; APOE E2/E3 F 70
CFH p. Y402H -/- M 87
bvFTD MAPT c.1920+16C>T +/- M 68
MAPT c.1920+16C>T +/- M 59
bFTD MAPT c.1920+16C>T +/- F 54
MAPT c.1920+16C>T +/- F 42
MAPT c.1920+16C>T +/- M 35
CMT4J FIG4 pI41T +/- M 27
DRPLA ATN1 CAG 13/66 +/- M 16
ATN1 CAG  17/57  +/- M 51
Friedreich’s ataxia FXN >75 GAA +/- M 21
FXN 8 GAA +/- M 44
FXN >75 GAA +/- F 17
FXN >66 GAA +/- M 23
FXN >75 GAA +/- M 34
FTD PRGN p.R493* +/- F 31
PRGN p.C31FS +/- M 65
FTDP VCP p.R155C +/- F 43
VCP p.R191Q +/- M 42
HD HTT CAG 18/39 +/- F 40-50
HTT CAG 17/42 +/- F 51
HTT CAG 14/127 +/- F 6
HTT CAG 14/127 +/- F 7
HTT CAG 28/66 +/- M 16
HTT CAG 17/38 +/- M 64
LCA CRB1 p.K801* +/-; p.C896* +/- F 4
CRB1 p.H447Pfs*7 +/-; p.K801* +/- F 4
Micropthalmia NM_0012026  c.-7-192G>A F 39
ML4 MCOLN1 p.F262S +/- F 36
NHD TREM2 p.W50C -/- F 41
TREM2 p.W50C  +/- M 68
SCA3 ATXN3 CAG 14/69 +/- M 50
ATXN3 CAG 26/70 +/- F 53
PD PINK1 p.W90Lfsx12 -/-; PRKN pR275W +/- F 48
PINK1 p.W90Lfsx12 +/-; PRKN p.R275W +/- M 75
PINK1 p.W9OLfsx12 -/- F 52
Retinopathy BEST1 p.N296S +/- M 69
BEST1 p.S231R +/- M 20
BEST1 p.A243V +/- F 50
EFEMP1 p.R345W +/- F 58
EFEMP1 p.R345W +/- M 64
EFEMP1 p.R345W +/- M 76
MERTK p.L623* +/-; p.D723N +/- F 24
MERTK p.R722* / multi-exon deletion +/- M 21
MERTK p.H721Q -/- F 18
SBMA AR >47 CAG M 66
SCA2 ATXN2 CAG  22/38 +/- M 41
ATXN2 CAG 22/36 +/- M 58
ATXN2 CAG 22/39 +/- F N/A
ATXN3 CAG 14/75 +/- F 22
CACNA1A CAG 23 +/- F 63
ATXN7  CAG 10/39 +/- F 61
USH1 MYO7A p.R1240Q +/-; p.K1255RfsTer8 +/- M 60
MYO7A p.D75H +/-; p.R2024* +/- F N/A